Thrombospondin-1-induced vascular smooth muscle cell migration is dependent on the hyaluronic acid receptor CD44

被引:19
|
作者
Maier, Kristopher G. [1 ,2 ,3 ]
Sadowitz, Benjamin [1 ,2 ,3 ]
Cullen, Sarah [1 ,2 ,3 ]
Han, Xuan [1 ,2 ,3 ]
Gahtan, Vivian [1 ,2 ,3 ]
机构
[1] SUNY Upstate Med Univ, Div Vasc Surg, Syracuse, NY 13210 USA
[2] SUNY Upstate Med Univ, Endovasc Serv, Syracuse, NY 13210 USA
[3] VA Healthcare Network, Dept Vet Affairs, Syracuse, NY USA
来源
AMERICAN JOURNAL OF SURGERY | 2009年 / 198卷 / 05期
关键词
Thrombospondin-1; CD44; Hyaluronic acid; Smooth muscle; Chemotaxis; Migration; Ras; PI3; kinase; EPIDERMAL-GROWTH-FACTOR; EXTRACELLULAR-MATRIX; ACTIVATION; MOTILITY; KINASES; PATHWAY; DISEASE;
D O I
10.1016/j.amjsurg.2009.07.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Thrombospondin-1 (TSP-1) induces vascular smooth muscle cell (VSMC) migration after arterial injury. TSP-1 up-regulates hyaluronic acid (HyA)-inducing genes in VSMCs. HyA also induces VSMC migration. Our hypothesis was that TSP-1-induced VSMC migration is dependent on the CD44 receptor, and that HyA and TSP-1 share migratory signaling pathways. METHODS: VSMC migration was assessed using TSP-1 HyA, or serum-free medium as chemoattractants. VSMCs were treated with inhibitors to CD44, Ras, phosphatidylinositol-3 kinase, Raf-1 kinase, or c-SRC. TSP-1- and HyA-induced epidermal growth factor receptor (EGFR) activity was determined by enzyme-linked immunosorbent assay. Comparisons were made by the Student t test and a P value less than .05 was considered significant. RESULTS: Inhibiting CD44 reduced TSP-1- and HyA-induced migration. Phosphatidylinositol-3 kinase and c-SRC inhibitors prevented TSP-1- and HyA-induced migration, whereas Ras and Raf-1 kinase inhibitors only affected TSP-1. TSP-1 and HyA activate the EGFR. CONCLUSIONS: TSP-1- and HYA-induced migration share some of the same signaling pathways and the EGFR/CD44 receptors may be a common link. (C) 2009 Elsevier Inc. All fights reserved.
引用
收藏
页码:664 / 669
页数:6
相关论文
共 50 条
  • [21] Cytokine regulation of CD44 gene expression in vascular smooth muscle cells
    Foster, LC
    Arkonac, BM
    Jain, M
    Perrella, MA
    Haber, E
    FASEB JOURNAL, 1996, 10 (06): : 871 - 871
  • [22] CD44 induction in smooth muscle cells during hypoxic vascular remodeling
    Danhaive, O
    Francalanci, P
    Peca, D
    Rota, R
    Orzalesi, M
    PEDIATRIC RESEARCH, 2004, 55 (04) : 96A - 96A
  • [23] Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid
    Ahrens, T
    Sleeman, JP
    Schempp, CM
    Howells, N
    Hofmann, M
    Ponta, H
    Herrlich, P
    Simon, JC
    ONCOGENE, 2001, 20 (26) : 3399 - 3408
  • [24] Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid
    Thomas Ahrens
    Jonathan P Sleeman
    Christoph M Schempp
    Norma Howells
    Martin Hofmann
    Helmut Ponta
    Peter Herrlich
    Jan C Simon
    Oncogene, 2001, 20 : 3399 - 3408
  • [25] Roles of and correlation between α-smooth muscle actin, CD44, hyaluronic acid and osteopontin in crescent formation in human glomerulonephritis
    Nakamura, H
    Kitazawa, K
    Honda, H
    Sugisaki, T
    CLINICAL NEPHROLOGY, 2005, 64 (06) : 401 - 411
  • [26] Localization and roles of (x-smooth muscle actin, CD44 and hyaluronic acid in tubulointerstitial fibrosis in IgA nephropathy
    Nakamura, H
    Kitazawa, K
    Sano, N
    Sugisaki, T
    9TH ASIAN PACIFIC CONGRESS OF NEPHROLOGY, 2003, : 287 - 290
  • [27] Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury
    Jain, M
    He, Q
    Lee, WS
    Kashiki, S
    Foster, LC
    Tsai, JC
    Lee, ME
    Haber, E
    JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (03): : 596 - 603
  • [28] Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies
    Mustafa, A
    McKallip, RJ
    Fisher, M
    Duncan, R
    Nagarkatti, PS
    Nagarkatti, M
    JOURNAL OF IMMUNOTHERAPY, 2002, 25 (06): : 476 - 488
  • [29] The hyaluronic acid receptor (CD44) is expressed in bovine oocytes and preimplantational stage embryos
    Valcárcel, A
    de Matos, DG
    Furnus, CC
    THERIOGENOLOGY, 1999, 51 (01) : 193 - 193
  • [30] Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
    Mattheolabakis, George
    Milane, Lara
    Singh, Amit
    Amiji, Mansoor M.
    JOURNAL OF DRUG TARGETING, 2015, 23 (7-8) : 605 - 618